Epidemiological Features and Risk Factors for Acquiring Hepatitis B, Hepatitis C, and Syphilis in HIV-Infected Patients in Shaanxi Province, Northwest China

Overview

Journal Int J Environ Res Public Health

Publisher MDPI

Specialties Environmental Health
Public Health

Date 2020 Mar 22

PMID 32197326

Citations 5

Authors

Chao Zhang

Qiang Ren

Wenhui Chang

Affiliations

Soon will be listed here.

Abstract

Human immunodeficiency virus (HIV)-infected patients are at a higher risk for co-infection with Hepatitis B virus (HBV), Hepatitis C virus (HCV), and Treponema pallidum (TP; the agent causing syphilis) than the general population. The prevalence of HBV, HCV, and syphilis has geographic differences and varies from region to region among HIV-positive individuals. A retrospective study was carried out on HIV-positive individuals between June 2011 and June 2016 in Shaanxi Province. Univariate and multivariate logistic regression analyses using stepwise regression analysis regarding risk factors for HIV-HBV, HIV-HCV, and HIV-syphilis co-infection. HBV-HCV, HCV-syphilis, HBV-syphilis, and HBV-HCV-syphilis co-infection rates were 1.7%, 2.2%, 2.6%, and 0.1%, respectively. The rate of ineffective hepatitis B vaccine immunization was as high as 30.2% among HIV-positive individuals. Ethnicity (OR = 31.030, 95% CI: 11.643-82.694) and HIV transmission routes (OR = 134.024, 95% CI: 14.328-1253.653) were the risk factors for HCV infection in HIV-positive individuals. Among the HIV-positive individuals with the antibodies of TP, the rate of homosexual transmission was also higher, but heterosexual transmission was lower (OR = 0.549 95% CI: 0.382-0.789) The HIV-infected patients in Shaanxi Province had the characteristics of low active detection rate and late diagnosis. The high rate of ineffective vaccination against HBV suggests a need for improved vaccination services.

Citing Articles

The impact of the National Syphilis Prevention Program on the prevalence of syphilis among people living with HIV in China: a systematic review and meta-analysis.

Zeng Q, Yang Y, Zhang L, Yan J, Wang J, Nie J J Int AIDS Soc. 2025; 28(1):e26408.

PMID: 39763073 PMC: 11705538. DOI: 10.1002/jia2.26408.

Seroprevalence of HIV, HBV, and syphilis co-infections and associated factors among pregnant women attending antenatal care in Amhara regional state, northern Ethiopia: A hospital-based cross-sectional study.

Anteneh D, Taye E, Seyoum A, Abuhay A, Cherkose E PLoS One. 2024; 19(8):e0308634.

PMID: 39116169 PMC: 11309376. DOI: 10.1371/journal.pone.0308634.

Factors associated with HIV/syphilis co-infection initiating of antiretroviral therapy.

Simoes L, Mendes J, Silveira M, Costa A, Lula M, Ceccato M Rev Saude Publica. 2022; 56:59.

PMID: 35766788 PMC: 9239423. DOI: 10.11606/s1518-8787.2022056003904.

HIV testing behaviors and willingness to receive oral rapid HIV testing among dental patients in Xi'an, China.

Gao B, Wang L, Santella A, Zhuang G, Huang R, Xu B PLoS One. 2021; 16(3):e0248585.

PMID: 33765025 PMC: 7993620. DOI: 10.1371/journal.pone.0248585.

Functional Gene Clusters in Global Pathogenesis of Clear Cell Carcinoma of the Ovary Discovered by Integrated Analysis of Transcriptomes.

Hsu Y, Wang P, Chang A Int J Environ Res Public Health. 2020; 17(11).

PMID: 32498447 PMC: 7312065. DOI: 10.3390/ijerph17113951.

References

Fu R, Zhao J, Wu D, Zhang X, Tucker J, Zhang M . A spatiotemporal meta-analysis of HIV/syphilis epidemic among men who have sex with men living in mainland China. BMC Infect Dis. 2018; 18(1):652. PMC: 6292157. DOI: 10.1186/s12879-018-3532-8. View

Lynn W, Lightman S . Syphilis and HIV: a dangerous combination. Lancet Infect Dis. 2004; 4(7):456-66. DOI: 10.1016/S1473-3099(04)01061-8. View

Hoffmann C, Thio C . Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis. 2007; 7(6):402-9. DOI: 10.1016/S1473-3099(07)70135-4. View

Branger J, van der Meer J, van Ketel R, Jurriaans S, Prins J . High incidence of asymptomatic syphilis in HIV-infected MSM justifies routine screening. Sex Transm Dis. 2008; 36(2):84-5. DOI: 10.1097/OLQ.0b013e318186debb. View

Wei Q, Lin H, Ding Y, Liu X, Wu Q, Shen W . Liver fibrosis after antiretroviral therapy in a longitudinal cohort of sexually infected HIV patients in eastern China. Biosci Trends. 2017; 11(3):274-281. DOI: 10.5582/bst.2017.01071. View

Chen X, He J, Ding L, Zhang G, Zou X, Zheng J . Prevalence of hepatitis B virus and hepatitis C virus in patients with human immunodeficiency virus infection in Central China. Arch Virol. 2013; 158(9):1889-94. DOI: 10.1007/s00705-013-1681-z. View

Aebi-Popp K, Wandeler G, Salazar-Vizcaya L, Metzner K, Stockle M, Cavassini M . Rapid decline of anti-hepatitis C virus (HCV) antibodies following early treatment of incident HCV infections in HIV-infected men who have sex with men. HIV Med. 2018; 19(6):420-425. DOI: 10.1111/hiv.12602. View

Kojima N, Klausner J . An Update on the Global Epidemiology of Syphilis. Curr Epidemiol Rep. 2018; 5(1):24-38. PMC: 6089383. DOI: 10.1007/s40471-018-0138-z. View

Kumar R, Singla V, Kacharya S . Impact and management of hepatitis B and hepatitis C virus co-infection in HIV patients. Trop Gastroenterol. 2009; 29(3):136-47. View

10.

Chung R . Hepatitis C and B viruses: the new opportunists in HIV infection. Top HIV Med. 2006; 14(2):78-83. View

11.

Arando Lasagabaster M, Guerra L . Syphilis. Enferm Infecc Microbiol Clin (Engl Ed). 2019; 37(6):398-404. DOI: 10.1016/j.eimc.2018.12.009. View

12.

Ning T, Guo Y, Zheng M, Bai J, Zhao X, Zhou N . [The characteristics of recent HIV-1 infection and associated factors in Tianjin]. Zhonghua Yu Fang Yi Xue Za Zhi. 2019; 53(3):323-326. DOI: 10.3760/cma.j.issn.0253-9624.2019.03.017. View

13.

Sulkowski M . Management of acute and chronic HCV infection in persons with HIV coinfection. J Hepatol. 2014; 61(1 Suppl):S108-19. DOI: 10.1016/j.jhep.2014.08.006. View

14.

Youssef E, Wright J, Delpech V, Davies K, Brown A, Cooper V . Factors associated with testing for HIV in people aged ≥50 years: a qualitative study. BMC Public Health. 2018; 18(1):1204. PMC: 6204048. DOI: 10.1186/s12889-018-6118-x. View

15.

de Ledinghen V, Barreiro P, Foucher J, Labarga P, Castera L, Vispo M . Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. J Viral Hepat. 2008; 15(6):427-33. DOI: 10.1111/j.1365-2893.2007.00962.x. View

16.

Degenhardt L, Charlson F, Stanaway J, Larney S, Alexander L, Hickman M . Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. Lancet Infect Dis. 2016; 16(12):1385-1398. DOI: 10.1016/S1473-3099(16)30325-5. View

17.

Baptista Lopes V, Hassing R, de Vries-Sluijs T, El Barzouhi A, Hansen B, Schutten M . Long-term response rates of successful hepatitis B vaccination in HIV-infected patients. Vaccine. 2013; 31(7):1040-4. DOI: 10.1016/j.vaccine.2012.12.047. View

18.

Sagnelli E, Sagnelli C, Macera M, Pisaturo M, Coppola N . An update on the treatment options for HBV/HCV coinfection. Expert Opin Pharmacother. 2017; 18(16):1691-1702. DOI: 10.1080/14656566.2017.1398233. View

19.

Easterbrook P, Sands A, Harmanci H . Challenges and priorities in the management of HIV/HBV and HIV/HCV coinfection in resource-limited settings. Semin Liver Dis. 2012; 32(2):147-57. DOI: 10.1055/s-0032-1316476. View

20.

OBryan T, Rini E, Okulicz J, Messner O, Ganesan A, Lalani T . HIV viraemia during hepatitis B vaccination shortens the duration of protective antibody levels. HIV Med. 2015; 16(3):161-7. DOI: 10.1111/hiv.12189. View